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Summary In 1985 a second randomisation was initiated for women in the treatment arm of the Scottish
Tamoxifen Trial either to stop tamoxifen at 5 years or to continue indefinitely. A preliminary analysis of
outcome in 342 patients at a median follow-up of 6 years suggests that a worthwhile gain in disease control
from continuing adjuvant tamoxifen beyond 5 years is unlikely. [Hazard ratio for events (relapse or death
without relapse) is 1.27, 95% CI=0.87-1.85.] There is a suggestion that therapy for longer than 5 years may
increase the risk of endometrial carcinoma (P=0.064).
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In 1987 we reported the results of the Scottish tamoxifen
trial, conducted between 1978 and 1984. (Breast Cancer
Trials Committee, 1987). In that trial, following mastectomy
for primary breast cancer, 1323 women were randomly
allocated either to receive adjuvant tamoxifen, 20 mg daily
for 5 years, or to a control group in which tamoxifen was to
be given only on relapse of disease. The results unequivocally
supported benefit from tamoxifen as adjuvant systemic
therapy. In 1984, we proposed that consenting disease-free
women in the study arm should be offered further
randomisation, at 5 years, to continue or to stop tamoxifen.
Methods
Eligibility for this second, subsidiary trial was disease-free
status after 5 years of continuous tamoxifen therapy in the
parent trial. Women entering the parent trial before March
1980 were ineligible, as most had already stopped tamoxifen.
At 41/2 years from entry, each subsequent patient believed to
be eligible had her secondary option selected in the Trials
Office by randomisation within each of five subgroups
(marked with an asterisk in Table I). The option was sent
in a sealed envelope to the clinician responsible for follow-up
in readiness for the 5th annual review. Only 2 of 90 clinicians
refused to participate. Provided eligibility criteria were
fulfilled and the patient consented to randomisation, the
envelope was opened, the appropriate instruction given and
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the Trials Office informed ofthe final decision. For only 53 of
the 395 eligible patients was the envelope returned unopened
or not used.
Between February 1985 and August 1989, 169 patients
were allocated to stop tamoxifen and 173 to continue. In the
event, 14 of the former decided to continue the drug and two
of the latter to stop. These 16 patients have been included in
the analysis as randomised in accordance with an intention-
to-treat policy. Follow-up and recording of information was
as in the parent trial, patients being seen annually or on
relapse. As many patients have since ceased routine hospital
review, progress reports have been obtained from their
general practitioners, resulting in information updated to
1993 for all but two patients. Median follow-up for living
patients from the date of rerandomisation was 6.2 (1.0-9.1)
years.
Results
The distribution of age at secondary randomisation and the
original characteristics of the patients and their tumours were
comparable (Table I). The median duration of tamoxifen
therapy for the 169 randomised to stop (including 14 who
refused to do so) is 60 (56-162) months and for the 173
randomised to continue (including two who elected to stop) is
128 (58-169) months. To date, 120 and 113 patients remain
alive and well in the 'stop' and 'continued' groups
respectively. A total of 105 (61%) of those randomised to
continue and 10 of the 14 who refused to stop remain on
tamoxifen; a further 11 in the 'continued' group elected to
stop after a median duration of 9 (6.5-11.5) years total use.
The distribution of events after rerandomisation at 5 years
is given in Table II, showing that the number with confirmed
relapse was greater, but not significantly so, in those
continuing tamoxifen (38) than in those stopping (28); 17
(61%) of the latter group restarted tamoxifen on relapse, at a
median interval after stopping of 47 (14-84) months. In six
patients in each group, relapse was deemed uncertain, being
of doubtful origin or of unknown site, although death was
certified as being due to breast cancer.
Event-free survival curves (for relapse or death without
relapse) are shown in Figure 1. The hazard ratio for theseTamoxifen duration trial in operable breast cancer
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Table I Characteristics of patients randomised to stop or to continue adjuvant tamoxifen
therapy after 5 years
Randomised option after 5 years
To stop tamoxifen To continue
Number of patients
Median age at entry (years) (range)
Original characteristics
Menstrual status
premenopausal
post-menopausal
Post-mastectomy XRT and node status*
No XRT given
node negative
node positive
no node identified
XRT given
node positive
no node identified
Oestrogen receptor status of primary tumour
0 - 19 fmol mg-' cytosol protein
20 fmol or more
No assay carried out
169 173
63 (36-81) 64 (39-82)
45
124
121
8
6
27
7
34
66
69
40
133
119
12
6
31
5
41
66
66
*Marks the five subgroups within which patients were randomised. XRT is post-operative
radiotherapy, given electively when node-positive sample and by random option when no node
identified.
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Figure 1 Kaplan-Meier curves for event-free survival in 342
patients with breast cancer, being alive and well after adjuvant
tamoxifen for 5 years and then randomised either to stop (-)
(169) or continue until relapse (- - -) (173). Hazard ratio is 1.27
favouring those randomised to stop, 95% confidence inter-
val =0.87- 1.85.
events is 1.27, with a 95% confidence interval of 0.87-1.85,
indicating a non-significant benefit for those randomised to
stop. The total number of deaths without relapse was similar
in the two groups; of them, nine patients died from cardiac
disease within 2-96 (median 72) months of stopping
tamoxifen compared with six who continued beyond 5 years
and died 1-13 months after rerandomisation.
Table III lists new primary tumours diagnosed after
secondary randomisation. Their distribution is similar in the
two arms with the exception of endometrial carcinomas,
which are confined to those continuing tamoxifen beyond 5
years (Fisher's exact test, P=0.064). No deaths from uterine
cancer have been recorded but in one patient the source of
the metastases causing death was doubtful.
Discussion
Indirect evidence from the combined analysis of tamoxifen
trials indicated that benefit from treatment for 2-5 years was
greater than that from less than 2 years (Early Breast Cancer
Table II Total events, excluding non-breast malignancies, since
secondary randomisation to stop or continue tamoxifen after 5 years
Randomised option after 5 years
To stop tamoxifen To continue
(169) (173)
Relapse confirmed
Alive 9 (7) 12
Dead I9a (10) 26a
Relapse in doubt-dead 6 6
Relapse not known-dead 15 16
aTwo patients ineach armwho died fromothercauses aftercomplete
excision oflocal orcontralateral disease. Figures inparentheses refer to
those who restarted tamoxifen on relapse.
Table III Second primary malignancies, in patients in the treatment
arm of the Scottish Adjuvant Tamoxifen Trial, diagnosed after re-
randomisation to stop or continue tamoxifen at 5 years
Random option after 5 years
ofadjuvant tamoxifen
To stop To continue
Contralateral breast 3 5
Endometiral 1 * 4
Ovarian 1 1
Large bowel/rectal 2 2
Bronchial 1 2
Other 5 4
*The only tumour listed where random option was not followed.
Trialists Collaborative Group, 1992). It seemed logical that
continuing tamoxifen for more than 5 years would confer
additional benefit but evidence of this is lacking in this
preliminary analysis.
The fewer events in those stopping tamoxifen at 5 years
lends some support to the view that prolonged tamoxifen
may induce tumour dependence on the drug (Wolf and
Jordan, 1993), but the size of the difference observed suggests
that this is not a common phenomenon.
Although not of statistical significance (P=0.064), we
believe it is of interest that endometrial carcinomas have
occurred only in those who continued tamoxifen beyond 5
years. This possible association with use for more than 5Tanoxifen duration rial m operable breast cancer
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years has not been suggested previously. Deaths from
cardiovascular disease do not appear to be greatly reduced
when therapy is continued.
A possible criticism ofthis study is the sample size, which is
not adequate to detect small differences between the treatment
groups. The trial size was limited by the availability in the
1980s of patients with 5 years successful adjuvant treatment
with tamoxifen, and this study is based on all patients
available to us. It represents the most mature trial of late
randomisation to continuous tamoxifen. Despite its limited
size, the confidence limits we report allow us to conclude that,
ifcontinuing tamoxifen beyond 5 years is beneficial, the extent
of that benefit is relatively modest, and not comparable with
the benefits seen in the first 5 years oftreatment. More precise
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estimates of the benefit and risk from long-term tamoxifen
would be welcome, and we would urge participation in
ongoing trials addressing this question. However, until such
evidence is accumulated. there is little to suggest that
tamoxifen should be prescribed routinely beyond 5 years.
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